AB
GYRE icon

Amalgamated Bank’s Gyre Therapeutics GYRE Stock Holding History

Amalgamated Bank’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-371
Closed -$3K – 2138
2025
Q4 		$3K Buy
371
+130
+54% +$1K ﹤0.01% 2855
2025
Q3 		$2K Hold
241
– – ﹤0.01% 2930
2025
Q2 		$2K Hold
241
– – ﹤0.01% 2962
2025
Q1 		$2K Hold
241
– – ﹤0.01% 2843
2024
Q4 		$3K Hold
241
– – ﹤0.01% 2848
2024
Q3 		$3K Hold
241
– – ﹤0.01% 2876
2024
Q2 		$3K Buy
+241
New +$3.31K ﹤0.01% 2915

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Amalgamated Bank's GYRE Position: Q1 2026 in Review

Amalgamated Bank sold out of Gyre Therapeutics (GYRE) in Q1 2026, closing a stake of 371 shares — an estimated $3K sold.

Amalgamated Bank first reported a position in GYRE in Q2 2024 and held it in 7 quarters. The position peaked at $3K in Q4 2025. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Amalgamated Bank reported no remaining Gyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 371 Gyre Therapeutics shares in Q1 2026, an estimated $3K.
  • Amalgamated Bank first reported a position in Gyre Therapeutics in Q2 2024 and held it in 7 quarters.
  • Amalgamated Bank's Gyre Therapeutics position peaked at $3K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.